Kornimate/medical-research-clean huggingface dataset:
dexpramipexole dose-ranging biomarker study in subjects with eosinophilic asthma

Conditions: Eosinophilic Asthma; Asthma

Summary: this is a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, multi-center study to evaluate the clinical effects of oral administration of dexpramipexole for 12 weeks on peripheral blood eosinophil count in subjects with eosinophilic asthma.

one hundred subjects will receive study drug or matching placebo over 12 weeks of consecutive dosing. following a short run-in period, eligible subjects will enter the primary assessment period and receive twice-daily dosing of study drug or placebo for 12 weeks. following 12 weeks of treatment, subjects will enter a 12-week eosinophil recovery period. the primary endpoint for the study is the change in blood absolute eosinophil count from baseline to week 12.

Eligibility criteria:
inclusion criteria: * male or female ≥18 and \<75 years of age at the time of consent * physician diagnosis of asthma for ≥12 months (relative to baseline) based on global initiative for asthma (gina) 2018 guidelines * asthma requiring treatment with, at a minimum, low dose inhaled corticosteroids in combination with a long-acting β2 agonist, on a stable dose for at least 1 month before screening * bronchodilator reversibility, as evidenced by ≥12% and ≥200 ml improvement in fev1 15 to 25 minutes following inhalation of albuterol at screening * pre-bronchodilator fev1 ≥40% and \<80% of predicted at screening and baseline * aec ≥0.30 x10\^9/l at the screening visit * acq-7 ≥1.5 at screening * negative pregnancy test at baseline * adherence ≥85% with twice-daily placebo taken during the run-in period exclusion criteria: * treatment for an asthma exacerbation within 8 weeks prior to baseline visit * treatment with systemic corticosteroids in the 8 weeks prior to screening * treatment with monoclonal antibody therapy, within 5-half-lives prior to baseline * treatment with selected drugs known to have a substantial risk of neutropenia * absolute neutrophil count \<2.0x10\^9/l at screening, or any documented history of absolute neutrophil count \<2.0x10\^9/l. * renal dysfunction, defined as an estimated glomerular filtration rate (egfr) \<60 ml/min/1.73m\^2 at screening * clinically significant abnormal laboratory or ecg values * other medically significant illness * use of any smoke or inhaled nicotine delivery device within 1 year prior to screening * pregnant women or women breastfeeding * currently taking pramipexole or other dopamine agonists

Keywords: eosinophilic asthma asthma dexpramipexole
the effect of 1l polyethylene glycol plus ascorbic acid with prepackaged low-residue diet for bowel preparation

Conditions: Colonoscopy; Colon Polyp; Bowel Preparation Solutions

Summary: background 2l polyethylene glycol plus ascorbic acid (pega) is known to be as effective as standard 4l polyethylene glycol for bowel preparation. however, the volume of this regimen is still large. therefore, the present investigators evaluated the potential of 1l pega with prepackaged low-residue diet (pld) for an alternative to 2l pega. aim: to evaluate efficacy of 1l peg with ascorbic acid combined with prepackaged low-residue diet as bowel preparation for colonoscopy. methods: the subjects were randomly assigned to either groups. pega group received 2l pega split regimen. pld group received pld on the day preceding colonoscopy and 1l pega on the morning of colonoscopy. one blinded physician performed colonoscopy and evaluated the degree of bowel preparation using boston bowel preparation score (bbps). a questionnaire regarding tolerability and safety were also gathered.


Eligibility criteria:
inclusion criteria: * anyone who were scheduled for an outpatient colonoscopy below indication 1. patient who need colonic polyp screening 2. patient who have hematochezia 3. patient who have fecal occult blood test positive result exclusion criteria: * ileus * inflammatory bowel disease- * gastrointestinal malignancy * severe cardiac disease (heart failure beyond nyha class iii) * chronic obstructive pulmonary disease, * decompensated liver cirrhosis; coagulopathy * female patients with pregnant or breastfeeding. * who use long-term use of sedative, anti-spasmodic, prokinetic, laxative or anti-diarrheal medications

Keywords: diet
dual-task cycling system on cognitive function for the elderly

Conditions: Cognitive Impairment

Summary: this project aims to develop a new dual-task stationary cycling system that can monitor and provide feedback on the aerobic exercise intensity, while administrating appropriate cognitive trainings targeting various cognitive sub domains through a screen in front of the user. the proposed system is designed to train the brain with cognitive tasks and the body with aerobic exercises at the same time. the difficulties of the cognitive tasks are controlled by the users' previous performances on these tasks so that they wouldn't be too easy nor too difficult. similarly, the intensity of the aerobic exercise will be monitored through an optical encoder for the cycling cadence, two power meters for the force output on the two pedals, as well as a heart rate monitor for the users' physiological response. constant feedback is being provided to the users so that they will exercise at the correct intensity to provide the greater cardiovascular and cognitive benefits.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of mci or cutoff at 2 \< n \< 16 th percentile moca score according to the level of education and age * sufficient cognitive ability to follow simple instructions * able to understand content and purpose of the study * conscious and in stable physical condition exclusion criteria: * any additional medical or psychological condition that would affect their ability to comply with the study protocol, e.g., a significant orthopaedic or chronic pain condition; or * severe hip, knee or ankle contracture that would preclude the passive range of motion of the leg * uncontrolled cardiac issues
instrumental and manual increase of couch in neuromuscular patients

Conditions: Neuromuscular Disease; Chronic Respiratory Failure; Coughing

Summary: inefficient cough is responsible of respiratory complications in neuromuscular patients which can lead to hospitalisation and can be life threatening. techniques enhancing cough efficiency are successful in improving the clearance of bronchial secretions and help non invasive ventilation efficiency especially in case of acute respiratory failure. combining mechanical exsufflation to the manual techniques of physiotherapy might enhance efficiency. therefore the investigators want to compare cough efficiency under different techniques of instrumental and manual of cough assistance in order to determine the best combination to optimize cough flow.

hypothesis: cough inefficiency in neuromuscular patients increases morbidity and mortality in case of airway infections and may lead to invasive ventilation. the use of techniques enhancing cough have been successful in improving the success of non invasive ventilation. we want to determine whether adding manual physiotherapist techniques to mechanical exsufflation improve cough efficiency and its ability to clear bronchial secretions. objectives: to compare cough flows obtained with different combination of the use of increased inspiratory capacity technique, mechanical insufflation-exsufflation technique and manually applied pressures techniques. method:open monocentric cross-over study (the patients are their own controls). five combinations of cough increase techniques are compared inclusion criteria: adult neuromuscular patients with a cough inefficiency at a stable state upon inclusion. as this is a pilot study, 20 patients from the home ventilation unit of the intensive care of the raymond poincare teaching hospital (garches, france) will be included during the usual follow-up of chronic respiratory failure.

Eligibility criteria:
inclusion criteria: * adult patients * neuromuscular disorders with a respiratory restrictive syndrome (vc \< 40% and/or cough flow \< 180 l/min and/or pe max \< 40 cmh2o) * non invasive ventilation * stable respiratory state \> 1 month before inclusion * signed informed consent form exclusion criteria: * unstable respiratory state with increased bronchial secretions * unstable hemodynamics * pneumothorax and or emphysema * tracheostomy * major bulbar involvement with swallowing dysfunction with the liquids * persons under guardianship or trusteeship * pregnant women * not covered by the social security system * refusal of study participation

Keywords: neuromuscular cough restrictive
the effectiveness of cognitive-functional remote group intervention (cog-fun rg) for adults with attention deficit hyperactivity disorder (adhd)

Conditions: ADHD

Summary: the goal of this clinical trial is to examine the effectiveness of cognitive-functional remote group intervention (cog-fun rg). the main questions of this study are 1. will participants demonstrate improvements in their executive functioning and quality of life after receiving the intervention, compared to waitlist controls. in addition, the investigators will examine if the waitlist group will demonstrate similar gains in these outcomes after receiving the same intervention. the investigators will compare between the intervention group to the waiting list group to examine the effect of the intervention. the participants will be allocated into two groups: an intervention group and a waiting list group. the intervention group will receive the the cog-fun rg intervention, which includes 21 weekly group sessions, each lasting 90 minutes. the participants will be required to complete questionnaires at several time points: pre-post the intervention, as well as three months, six months, and one year after the intervention. the waiting list controls will be required to complete questionnaires at several time points: pre-post waiting period, and then after the intervention, as well as three months, six months, and one year after the intervention.


Eligibility criteria:
inclusion criteria: \* self reported adhd diagnoses exclusion criteria: \* self reported other major health condition that impedes daily functioning

Keywords: occupational therapy executive functions remote group therapy
effect of candesartan in alcoholic liver fibrosis

Conditions: Alcoholic Liver Disease

Summary: background: alcohol is one of principal causes of hepatic fibrosis. although the most effective treatment for alcoholic hepatic fibrosis is abstinence of alcohol consumption, additive treatment to reduce the accumulation of scar tissue can accelerate the improvement of hepatic fibrosis in alcoholic liver disease. the renin-angiotensin system can be an attractive antifibrotic target in liver. several lines of evidence indicate that overproduction of angiotensin ii(ang ii) in chronic liver injury stimulates the activation of hepatic stellate cells(hscs) attributed to fibrogenesis. additionally, the antifibrotic effect of ang ii blocking agent has been shown in various animal models and hepatitis c patients. hence, drugs that inhibit the renin-angiotensin system have promise in ameliorating hepatic fibrosis in chronic liver injury. however, no study has been conducted in patients with alcoholic liver disease to evaluate the effect ang ii type i receptor blocking agent on hepatic fibrosis. aim: this study aimed to investigate the safety and the efficacy of chronic administration of candesartan to hepatic fibrosis patients with alcoholic liver disease. methods 1) patients with liver fibrosis(f2) were randomized to receive either the angiotensin receptor blocker(arb), candesartan(8 mg/day) with ursodeoxycholic acid(udca)(600 mg/day)(n = 42), or udca alone(n = 43) as control for 6 months. 2)all enrolled patients underwent liver biopsies twice for measurement of fibrosis score, area of fibrosis and alpha-smooth muscle actin(sma) positive and hydroxyproline. 3) transforming growth factor-beta1(tgf-beta1), collagen-1, angiotensin ii type i receptor(at1-r), tissue inhibitor of metalloproteinase-1(timp-1), rac1 and p22phox which represent oxidant stress were also measured by real-time rt-pcr before and after 6 months of therapy.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of alcoholic liver disease * metavir fibrosis score ≥ 2 in liver biopsy * alcohol intake has stop during at least 6 months until study enrollment exclusion criteria: * hepatocellular carcinoma or other malignancy * clinically decompensated cirrhosis (total bilirubin ≥ 5mg/dl or variceal hemorrhage or ascites development or hepatic encephalopathy developement) * chronic liver disease related with other causes except alcohol

Keywords: hepatic fibrosis angiotensin ii blocking agents alcoholic liver disease
reducing symptoms of multiple sclerosis using non-invasive neuromodulation

Conditions: Multiple Sclerosis

Summary: this study sought to examine the effect of targeted physical therapy with and without cranial nerve non-invasive neuromodulation (cn-ninm), on the walking ability of people with ms who exhibited a dysfunctional gait.

background: this study sought to examine the effect of targeted physical therapy with and without cranial nerve non-invasive neuromodulation (cn-ninm), on the walking ability of people with ms who exhibited a dysfunctional gait. the investigators hypothesized that subjects who received electrical stimulation would have greater improvement than those who had a control device after a 14-week intervention. gait disturbance is a common problem for people with multiple sclerosis (ms). the investigators have developed an effective rehabilitative strategy using neuromodulation of the cranial nerves via electrical stimulation of the tongue to enhance the plasticity of the brain. methods: the study is a within-subject blinded randomized control design. twenty chronic ms subjects with an identified gait disturbance were assigned to either an active or control group. both groups completed a 14-week intervention program using a standardized combination of exercise and a device that provided electrical stimulation to the tongue. those in the active group received electrical stimulation on the tongue that they could perceive. those in the control group used a device that did not provide a physiologically significant stimulus and was not perceivable. subjects were assessed with the dynamic gait index (dgi).

Eligibility criteria:
all subjects are initially evaluated for inclusion/exclusion on the kurtzke expanded disability status scale (edss), a test typically administered by their healthcare provider as an ongoing part of standard therapy for m.s inclusion criteria: * relapsing remitting ms ("rrms"), primary progressive ms ("ppms"), or secondary progressive ms ("spms") without relapse within 6 months of enrollment; * edss score of 3.0 - 6.0 ; * no changes in medication within 3 months of enrollment; * ability to walk 20 minutes on a treadmill (with handrail support as needed) without rest; * provided informed consent and willing to participate. exclusion criteria: • major co-morbidities, especially other neurological disorders, uncontrolled pain, hypertension, diabetes, or oral health problems
effect of the benson relaxation technique on clinical outcomes of oncology patients admitted to intensive care units

Conditions: Oncology Patients; Relaxation Program

Summary: the benson relaxation technique (brt), developed by dr. herbert benson, is a method aimed at reducing stress and anxiety through a series of simple steps designed to elicit the "relaxation response." this response is a physiological state that counteracts the harmful effects of stress, characterized by decreased heart rate, lower metabolism, and reduced breathing rate

the benson relaxation consisted of the following steps: (1) sitting or lying down quietly in a comfortable position; (2) closing eyes; (3) deeply relaxing all muscles, beginning at the feet and progressing up to the face. keeping them relaxed; (4) breathing through the nose. becoming aware of breathing. focus on a word, phrase, a short prayer, or only breathing. (6) continuing for 15 minutes. when finished, sit quietly for several minutes, at first with eyes closed and later with eyes opened. do not stand up for a few minutes. according to the agreement, the patients in both groups were required to perform the benson relaxation technique regularly twice daily (morning and evening) for three days in a row. each session lasted 15 minutes

Eligibility criteria:
inclusion criteria: * adult patients aged 18-60 years * diagnosed with cancer * alert and able to communicate. exclusion criteria: * patients who refused to participate in the study * patients with cognitive impairment * patient who unable to communicate

Keywords: benson relaxation oncology/ cancer patients clinical outcomes
covid-19 pcr test results in asymptomatic pregnants

Conditions: COVID-19; Asymptomatic Pregnant

Summary: in order to prevent contamination from the pregnant women hospitalized in this clinic, the rt-pcr test is performed from the oropharyngeal and nasal swab sample taken before hospitalization. in addition, the same test is done before each operation and before the operation. the aim of the study is to scan these tests retrospectively and to determine the rate of positive covid-19 cases in asymptomatic pregnant women. the results will determine the importance of the measures to be taken in the pregnant women who undergo intervention.


Eligibility criteria:
inclusion criteria: * asymptomatic pregnant women who will give birth in this clinic, dilatation and curettage due to missed abortion, cerclage due to cervical insufficiency, medical evacuation due to fetal anomaly, and routine pcr test taken for service for some treatments. exclusion criteria: * having any covid-19 infection symptoms (fever, cough, weakness, shortness of breath, sore throat, etc.)
anti-cd19 u-car-t cell therapy for b cell hematologic malignancies

Conditions: B-cell Acute Lymphoblastic Leukemia; B-cell Lymphoma

Summary: the stunning response rate of anti-cd19(cluster of differentiation antigen 19) auto-car(chimeric antigen receptor)-t cell therapy brings hope to patients with relapsed or refractory b-cell hematologic malignancies. however, based on open clinical trials, using patients' t cells might encounter the failure of apheresis available t cells, even if successful, the time needed for the manufacture could also cause the irreversible disease progress. furthermore, the cost of auto-car-t cells is not affordable for most patients. so to provide an accessible and affordable anti-cd19 car-t cell therapy for patients with b-cell hematologic malignancies, we launch such a trial that using the edited t cells from healthy donors to manufacture universal car-t cells and adapt it in patients with cd19+ b-cell leukemia or lymphoma.


Eligibility criteria:
inclusion criteria: * 1. diagnosis of recurrent b-cell acute lymphoblastic leukemia (b-all), b-cell acute lymphoblastic lymphoma (b-lly), or b-non-hodgkin lymphoma (b-nhl) 2. cd19-positive tumor (≥20% cd19 positive blasts by flow cytometry or immunohistochemistry (tissue)） 3. hgb ≥ 7.0 (can be transfused) 4. life expectancy greater than 12 weeks 5. informed consent explained to, understood by and signed by the patient/guardian. the patient/guardian is given a copy of informed consent. exclusion criteria: 1. pregnant or lactating. 2. tumor in a location where enlargement could cause airway obstruction (per investigator discretion). 3. active infection with hiv or htlv. 4. clinically significant viral infection or uncontrolled viral reactivation of ebv(epstein-barr virus), cmv(cytomegalovirus), adv(adenovirus), bk-virus, or hhv(human herpesvirus)-6. 5. any of the following cardiac criteria: atrial fibrillation/flutter; myocardial infarction within the last 12 months; prolonged qt syndrome or secondary prolonged qt, per investigator discretion. cardiac echocardiography with lvsf (left ventricular shortening fraction)\<30% or lvef(left ventricular ejection fraction)\<50%; or clinically significant pericardial effusion. cardiac dysfunction nyha(new york heart association) iii or iv (confirmation of absence of these conditions on echocardiogram within 12 months of treatment). 6. cns abnormalities: presence of cns(central nervous system)-3 disease defined as detectable cerebrospinal blast cells in a sample of csf(cerebrospinal fluid) with ≥ 5 wbc( white blood cell)s per mm3 (unless negative by the steinherz/bleyer algorithm); presence of any cns disorder such as an uncontrolled seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with cns involvement.
rehabilitation training participated by caregivers in ischemic stroke: a randomized controlled trial to test the effect of home-based rehabilitation intervention on physical function.

Conditions: Ischemic Stroke; Physical Disability

Summary: the goal of this clinical randomized control trial is to test the effect of home-based motor rehabilitation training participated by caregivers on physical function in patients with ischemic stroke \]. the main question\[s\] it aims to answer are: * dose this kind of intervention method can improve the function of ischemic cerebral apoplexy patients is physical activity? * does this intervention reduce the caregiver-related burden of patients with ischemic stroke? participants will be randomly assigned to: (1) home-based motor rehabilitation training participated by caregivers (intervention group or (2) routine self-care group (control group). both groups will receive assessment and health guidance on the day of discharge, with the intervention group receiving an additional home-based training program and supervision. the two groups will be followed up every week after discharge. researchers will compare two groups to see if has great effects on physical function.


Eligibility criteria:
inclusion criteria: * patient inclusion criteria: (1) according to the international classification of diseases (icd) definition of ischemic cerebral apoplexy, conform to the guidelines of diagnosis and treatment of acute ischemic stroke in china 2018 "diagnostic criteria, and confirmed by craniocerebral ct or mri in the diagnosis of ischemic cerebral apoplexy patients. (2) on the day of discharge nihss score 15 points or less; (3) the patient's vital signs are stable and have clear consciousness.; (4) patients and their families for research cooperation and positive cooperation attitude. * caregiver inclusion criteria:1）who is an adult (18 years old or older); 2) physically healthy, with normal cognitive ability, living ability, language communication ability and learning ability;3) be the primary caregiver exclusion criteria: * patients' exclusion criteria: 1) patients with unstable vital signs or unclear consciousness; 2) patients who are unable to express language correctly due to aphasia or dysarthria; 3) the nihss score of the patient was more than 15 on the day of discharge; 4) patients with other serious chronic or malignant diseases. * caregiver' exclusion criteria: 1) who with tumor, history of major surgery and history of severe trauma; 2) with mental illness

Keywords: ischemic stroke rehabilitation home nursing caregiver physical function caregiver burden